Paul Ashton
Company: Inflammasome Therapeutics
Job title: President & Chief Executive Officer
Seminars:
Inflammasome Inhibition: The new Anti-VEGFs? 3:00 pm
Upregulation of inflammasomes in ocular disease Inhibition inflammasomes in pre-clinical models Big data and clinical proof of conceptRead more
day: Conference Day 2
Panel & Live Audience Discussion: Reviewing & Establishing the Translational Challenges of Accelerating Neovascularization Drugs into the Clinic & Beyond 1:30 pm
Capabilities and limitations of current pre-clinical models in allowing translatable research in nAMD / DME and DR Finding optimal clinical biomarkers and endpoints for different development stages in Wet AMD / DME/ DR Reviewing the need for updated regulatory guidelines for the measurements of efficacy and safety endpoints such as visual acuity, for the new…Read more
day: Conference Day 2